The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Sterling Pharma Solutions, a globally active CDMO based in Birmingham, England, has kicked off a $2.1 million expansion project to increase chemical and analytical capabilities at its facility at Cary, North Carolina, in the heart of the US state’s Research Triangle. The work is scheduled to be completed by the end of this year, allowing the recruitment of up to 20 additional scientists, the company said.
UK CDMO Sterling Pharma Solution has announced the next phase of a multi-year investment at its site in Dudley. The £10m project will include new process development laboratories plus the installation of additional commercial-scale production equipment to meet the ongoing growth in demand for small molecule API manufacturing.
UK CDMO Sterling Pharma Solutions has acquired compatriot firm ADC Biotechnology, a specialist in antibody drug conjugates (ADCs). The acquisition follows Sterling’s “significant” investment in the business last December, which was made with a view to acquiring ADC Bio in the first quarter of 2021.
CDMO Sterling Pharma Solutions has formed a strategic partnership with ADC Biotechnology, a UK-based specialist in the discovery, development and manufacture of antibody drug conjugates.
